Daré Bioscience to Present Implantable Device in Boston
The company will showcase its DARE-IDDS platform during the upcoming PODD 2026 conference on October 30.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Would you trust an implantable device to manage your long-term medication doses instead of manual injections?
Daré Bioscience is set to present its DARE-IDDS implantable device at the 16th annual PODD 2026 conference in Boston. The presentation is scheduled to take place on October 30, 2026.
Why it matters
The DARE-IDDS device aims to improve patient outcomes by providing a long-acting, reversible option that mitigates challenges associated with chronic, daily injection-based therapies.
The DARE-IDDS is a subcutaneous implantable device capable of storing and delivering more than 100 doses. It integrates programmable drug delivery with wireless communication capabilities.
The players
Daré Bioscience
This San Diego-based biopharmaceutical company focuses on developing innovative products for women's health.
Cambridge Consultants
This technology development firm collaborated with Daré Bioscience to advance the technical DARE-IDDS platform.
Liz Proos
She is scheduled to present the latest developments regarding the DARE-IDDS device at the conference.
The details
Developed in collaboration with Cambridge Consultants, the platform is currently in preclinical development and has not yet received approval for human use. While initially intended for long-acting contraception, the technology is being designed with potential applications across various other therapeutic fields.
Timeline
October 29-30, 2026: The PODD 2026 conference takes place in Boston.
October 30, 2026: Liz Proos delivers the device presentation at 2:30 p.m. ET.
The Tech Race
The DARE-IDDS platform represents a next-generation evolution of traditional implantable contraceptive devices by adding programmable wireless delivery. This shift marks a move toward smart, digital health solutions replacing manual injection-based regimens.
For patients requiring chronic injections, this technology could eventually replace frequent clinical visits or daily self-administration with a long-acting, automated device. However, the device remains in preclinical development and is not currently available for consumer use.
The takeaway
The development of programmable implants highlights a growing industry trend toward automating long-term medication delivery. Patients should continue to rely on traditional, physician-approved injection therapies until these new platforms complete rigorous clinical testing and regulatory review.
Further reading
For more information on the latest innovations in the field, explore the Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Would you trust an implantable device to manage your long-term medication doses instead of manual injections?
